Replimune (REPL) Non Operating Income (2017 - 2026)
Replimune (REPL) posted Non Operating Income of -$119000.0 for Q1 2026, down 118.98% sequentially from $627000.0 in Q4 2025, and down 102.34% YoY from $5.1 million in Q1 2025.
Replimune (REPL) Non Operating Income (2017 - 2026) Analysis & Trends
Replimune has reported Non Operating Income for 10 years, with the latest figure at -$119000.0 in Q1 2026.
- Quarterly Non Operating Income fell 102.34% year-over-year to -$119000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (down 63.33% YoY) and the FY2026 annual result came in at $5.4 million, down 63.32% from the prior year.
- Non Operating Income slipped to -$119000.0 in Q1 2026 per REPL's latest filing, from $627000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $6.3 million in Q2 2023 and troughed at -$1.5 million in Q3 2022.
- A 5-year average of $2.5 million and a median of $3.6 million in 2023 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 7983.33% in 2022, down 2067.14% in 2022.
- Over 5 years, Non Operating Income stood at $1.9 million in 2022, then jumped by 203.76% to $5.9 million in 2023, then sank by 95.69% to $254000.0 in 2024, then jumped by 146.85% to $627000.0 in 2025, then tumbled by 118.98% to -$119000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$119000.0, $627000.0, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | -119,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -119,000.00 |
| Dec 31, 2025 | 627,000.00 |
| Sep 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 3.73 Mn |
| Mar 31, 2025 | 5.09 Mn |
| Dec 31, 2024 | 254,000.00 |
| Sep 30, 2024 | 5.86 Mn |
| Jun 30, 2024 | 3.60 Mn |
| Mar 31, 2024 | 3.62 Mn |
| Dec 31, 2023 | 5.89 Mn |
| Sep 30, 2023 | 3.59 Mn |
| Jun 30, 2023 | 6.29 Mn |
| Mar 31, 2023 | 4.04 Mn |
| Dec 31, 2022 | 1.94 Mn |
| Sep 30, 2022 | -1.52 Mn |
| Jun 30, 2022 | -1.38 Mn |
| Mar 31, 2022 | 292,000.00 |
| Dec 31, 2021 | 24,000.00 |
| Sep 30, 2021 | -108,000.00 |
| Jun 30, 2021 | 70,000.00 |